MDxHealth Announces its Extraordinary General Shareholders’ Meeting
06 6월 2023 - 6:30AM
MDxHealth Announces its Extraordinary General Shareholders’ Meeting
NEWS
RELEASE – REGULATED INFORMATION JUNE
5, 2023,
5:30 pm ET/
23:30
CEST
MDxHealth Announces its
Extraordinary General Shareholders’
Meeting
IRVINE, CA, and
HERSTAL, BELGIUM – June 5, 2023 –
MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the
"Company" or
"mdxhealth"), a commercial-stage
precision diagnostics company, today invites the holders of
securities issued by the Company to its extraordinary general
shareholders' meeting that will be held on Friday, June 30, 2023 at
9:00 a.m., Belgian time.
The items on the agenda of the extraordinary
general shareholders' meeting include the issuance of a new share
option plan called the "2023 Share Option Plan" and the renewal of
the authorization to the board of directors to increase the share
capital within the framework of the authorized capital.
In order to participate to the extraordinary
general shareholders’ meeting of the Company, the holders of
securities issued by the Company must comply with article 7:134,
§2, first indent of the Belgian Companies and Associations Code and
the articles of association of the Company, and fulfill the
formalities described in the convening notice. The convening
notice, forms and other documents relating to the extraordinary
general shareholders’ meeting can be consulted on the Company’s
website.
The Company recommends holders of its securities
to use e-mail for all communication with the Company regarding the
general shareholders' meeting. The Company's email address for such
communication is: agsm@mdxhealth.com.
About mdxhealth®
mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
For more
information:mdxhealthinfo@mdxhealth.com
LifeSci Advisors (IR & PR)US: +1 949 271
9223ir@mdxhealth.com
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
MDxHealth (EU:MDXH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
MDxHealth (EU:MDXH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024